ReviewNature reviews. Cancer2026
Targeting phagocytosis checkpoints for cancer immunotherapy.
Review in Nature reviews. Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity.Biomolecules · 2026Review
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- IQGAP2 regulates phagocytic-like activity and PD-L1 expression in glioma through the JAK2/STAT3 axis.Molecular biology reports · 2026Article
- Transgenic expression of human signal regulatory protein alpha (SIRPα) in BALB/c Rag2Transgenic research · 2026Article
- Covalent tumor anchoring spatially orchestrates antitumor immunity.bioRxiv : the preprint server for biology · 2026Article
- Molecular insights for the tumor suppressor role of SPOP in prostate cancer.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- CAR-macrophages: a new chapter in cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026Article
- An IGF2BP2-MYBL2-HMGB2 Signaling Axis Promotes Macrophage Immune Evasion in Hepatocellular Carcinoma.Cancer communications (London, England) · 2026Article
- NK cell hyperactivation drives macrophage repolarization and limits M2 bias in pemphigus vulgaris.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability of macrophages to eliminate cancer cells through phagocytosis is tightly controlled by pro-phagocytic and inhibitory phagocytic receptors. Pro-phagocytic receptors such as Fc receptors, macrophage-1 antigen (MAC-1; also known as CD11b/CD18) and signalling lymphocytic activation molecule family member 7 (SLAMF7) have been shown to facilitate tumour cell elimination in pre-clinical models, and Fc receptors have been determined critical for the anti-tumour efficacy of several monoclonal antibodies in the clinic. Pre-clinical and early clinical studies have also highlighted that blocking of inhibitory phagocytic checkpoints, most prominently signal-regulatory protein α (SIRPα) and its ligand CD47, is a promising therapeutic approach for cancer. However, concerns about limited efficacy and toxicities in recent clinical trials have led to diminished enthusiasm for this approach. In this Review, we examine the evidence supporting phagocytic checkpoints as targets for cancer therapy, while highlighting current challenges associated with this therapeutic strategy. We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
Indexed as
Identifiers
41360986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.